Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384157 | 0.98 | LMNA (0.69) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13055383 | 0.90 | LMNA (0.80) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL6494174 | 0.89 | HTT (0.70) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL14463120 | 0.88 | HTT (0.68) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL7907549 | 0.88 | HTT (0.68) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL19527223 | 0.88 | HTT (0.68) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL4506331 | 0.87 | LMNA (0.71) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL10243339 | 0.87 | LMNA (0.71) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL8428000 | 0.85 | LMNA (0.69) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL27543692 | 0.85 | LMNA (0.69) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402037-B1 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20150148284-A1 | Controlled Release of Phenolic Opioids | PHARMACOFORE, INC. | 2015-05-28 | — | — | US | disclosed |
| US-8921418-B2 | Controlled release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2046393-B1 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20120270894-A1 | Controlled Release of Phenolic Opioids | 3I, LP | 2012-10-25 | — | — | US | disclosed |
| US-8217005-B2 | Controlled release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2402037-A1 | Controlled release of phenolic opioids | Pharmacofore, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110105381-A2 | Prodrugs of Peripheral Phenolic Opioid Antagonists | PHARMACOFORE, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20100267614-A1 | Prodrugs of Peripheral Phenolic Opioid Antagonists | PHARMACOFORE, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100035826-A1 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | Phamacofoce, Inc. (CA) | 2010-02-11 | — | — | US | disclosed |
| EP-2046393-A2 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | Pharmacofore, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008101187-A2 | PRO-DRUGS OF PERIPHERAL PHENOLIC OPIOID ANTAGONISTS | PHARMACOFORE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007140272-A2 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | PHARMACOFORE, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-7090828-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-6818201-B2 | FOR ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; USEFUL FOR IMAGING ATHEROSCLEROSIS, RESTENOSIS, CARDIAC ISCHEMIA AND MYOCARDIAL REPERFUSION INJURY; THERAPY OF RHEUMATOID ARTHRITIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-16 | — | — | US | disclosed |
| US-20040014964-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030143235-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6569402-B1 | Targeting moiety that binds to receptor upregulated during angiogenesis, and a radioisotope or diagnostically imageable moiety; receptor integrin and compound is a benzodiazepine, benzodiazepinedione, or dibenzotrihydroannulene nonapeptide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-27 | — | — | US | disclosed |
| US-6558649-B1 | Benzodiazepine nonpeptide targeting moiety bound to chelating group; diagnosis and treatment of cancer; imaging tumors; monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143235-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, ADGRE5 | GAA 3764/4885CA2 3206/4885LMNA 168/4885 |
| US-20120270894-A1 | Controlled Release of Phenolic Opioids | OPRK1, OPRM1, OPRD1 | GAA 669/4885CA2 658/4885LMNA 4070/4885 |
| US-20150148284-A1 | Controlled Release of Phenolic Opioids | OPRK1, OPRM1, OPRD1 | GAA 669/4885CA2 658/4885LMNA 4070/4885 |
| US-20110105381-A2 | Prodrugs of Peripheral Phenolic Opioid Antagonists | OPRM1, OPRL1, OPRK1 | GAA 3703/4885CA2 4102/4885LMNA 1983/4885 |
| US-20100035826-A1 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | OPRK1, OPRM1, OPRD1 | GAA 669/4885CA2 658/4885LMNA 4070/4885 |
| US-20040014964-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | GAA 3952/4885CA2 3290/4885LMNA 137/4885 |
| US-20100267614-A1 | Prodrugs of Peripheral Phenolic Opioid Antagonists | OPRM1, OPRK1, OPRL1 | GAA 3740/4885CA2 4091/4885LMNA 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.